Andree Zibert

Andree Zibert

Auto-generated profile, based on publicly available information

Andree Zibert

Medizinische Klinik B, Universitätsklinikum Münster, Münster, Germany

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2004 in Blood
Verified
Journal Article
Open access
PDF file
RMRoland Meisel
Roland Meisel
AZAndree Zibert
Andree Zibert
MLMaurice Laryea
Maurice Laryea
UGUlrich Göbel
Ulrich Göbel
WDWalter Däubener
Walter Däubener
DDDagmar Dilloo
Dagmar Dilloo
Marrow stromal cells (MSCs) inhibit allogeneic T-cell responses, yet the molecular mechanism mediating this immunosuppressive effect of MSCs remains controversial. Recently, expression of indoleamine 2,3-dioxygenase (IDO), which is induced by interferon-γ (IFN-γ) and catalyzes the conversion from tryptophan to kynurenine, has been identified as a T-cell inhibitory effector pathway in professional antigen-presenting cells. Here we show that human MSCs express IDO protein and exhibit functional IDO activity upon stimulation with IFN-γ. MSCs inhibit allogeneic T-cell responses in mixed lymphocyte reactions (MLRs). Concomitantly, IDO activity resulting in tryptophan depletion and kynurenine production is detected in MSC/MLR coculture supernatants. Addition of tryptophan significantly restores allogeneic T-cell proliferation, thus identifying IDO-mediated tryptophan catabolism as a novel T-cell inhibitory effector mechanism in human MSCs. As IDO-mediated T-cell inhibition depends on MSC activation, modulation of IDO activity might alter the immunosuppressive properties of MSCs in different therapeutic applications. (Blood. 2004;103:4619-4621)

1 March 2019 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
EPElena V. Polishchuk
Elena V. Polishchuk
AMAssunta Merolla
Assunta Merolla
JLJosef Lichtmannegger
Josef Lichtmannegger
ARAlessia Romano
Alessia Romano
AIAlessia Indrieri
Alessia Indrieri
RPRoman Polishchuk
Roman Polishchuk

1 April 1995 in Virology
Verified
Journal Article
Closed access
PDF file
AZAndree Zibert
Andree Zibert
ESEckart Schreier
Eckart Schreier
MRMichael Roggendorf
Michael Roggendorf

30 June 1994 in Journal of Virological Methods
Verified
Journal Article
Closed access
SVSergei Viazov
Sergei Viazov
AZAndree Zibert
Andree Zibert
KRKandiah Ramakrishnan
Kandiah Ramakrishnan
AWAnders Widell
Anders Widell
ACAda Cavicchini
Ada Cavicchini
MRMichael Roggendorf
Michael Roggendorf

1 May 1997 in Hepatology
Verified
Journal Article
Open access
PDF file
AZA Zibert
A Zibert
HMH Meisel
H Meisel
WKW Kraas
W Kraas
ASA Schulz
A Schulz
GJG Jung
G Jung
MRM Roggendorf
M Roggendorf
Antibodies directed to hypervariable region 1 (HVR1) of hepatitis C virus (HCV) have recently been shown to neutralize the corresponding HCV isolate in vitro. We analyzed the appearance of antibodies directed to HVR1 during the course of infection in a large group of patients who have been infected by the same isolate of a HCV contaminated anti-D immunoglobulin (HCV-AD78). An enzyme-linked immunosorbent assay (ELISA) was established using a synthetic peptide to detect antibodies against the main HVR1 variant of HCV-AD78. 207 sera obtained at different time points post infection (p.i.) of 51 patients having either acute self- limiting (n = 28) or chronic infection (n = 23) were studied. Antibodies directed to HVR1 were found at least at one time point during the infection course in 15 of 28 patients (53%) having acute self-limiting infections and in 17 of 23 patients (74%) with chronic disease. The time of appearance of anti-HVR1 was significantly different between these two patient groups (P < .025) although appearance and titers of other HCV-specific antibodies were found to be similar at early time points p.i. In acute self-limiting infections 9 of 21 sera (43%) of respective patients with sera available within the first 6 months p.i. were anti-HVR1 positive. The highest prevalence of anti-HVR1 in this group of patients was within month 6 to 12 p.i. (64%). None of the sera available after 24 months p.i. had such antibodies. In contrast, only 2 of 15 sera (13%) of chronically infected patients with respective time points of sera were anti-HVR1 positive within the first 6 months p.i. and only 5 of 18 sera (28%) were positive within month 7 to 12 p.i. Seven patients with chronic HCV infections showed at least two consecutive anti-HVR1 negative early time points up to month 18 p.i. Prevalence of anti-HVR1 after 24 months p.i. was high (84%) in this group of patients and most of the patients maintained high levels of anti-HVR1 for up to 17 years p.i. Our findings suggest clearance of virus by respective neutralizing antibodies resulting in a self-limiting infection and may have implications for prognosis of the disease and also for any future vaccine development.

4 August 2021 in Frontiers in Immunology
Verified
Journal Article
Open access
PJPhilipp Jörrißen
Philipp Jörrißen
PSPaula Schütz
Paula Schütz
MWMatthias Weiand
Matthias Weiand
RVRichard Vollenberg
Richard Vollenberg
ISInga Marie Schrempf
Inga Marie Schrempf
AZAndree Zibert
Andree Zibert
Understanding the course of the antibody response directed to individual epitopes of SARS-CoV-2 proteins is crucial for serological assays and establishment of vaccines. Twenty-one synthetic peptides were synthesized that have ten amino acids overlap and cover the complete membrane (M) protein. Plasma samples from 32 patients having acute disease and 30 patients from the convalescent phase were studied. Only peptide M01 (aa 1–20) and to a lesser extent peptide M21 (aa 201–222) showed specific reactivity as compared to historical control plasma samples. Peptide M01 was recognized by IgM- (71.9%) and IgG-specific antibodies (43.8%) during the acute phase as early as day 8 PIO. In a longitudinal analysis, a higher reactivity was observed for the IgM response directed to peptide M01 following day 20 PIO as compared to earlier time points of the acute phase. In the convalescent phase, antibody reactivity to the two M-specific peptides was significantly lower (<30% seropositivity). A fusion protein encoding major parts of RBD also showed higher rates of recognition during acute (50.0%) and lower rates in the convalescent phase (23.3%). Taken together, our results suggest that during the acute phase of COVID-19 antibodies are raised to two linear epitopes of the SARS-CoV-2 M protein, located at the very N- and C-termini, showing almost similar levels of reactivity as immunodominant linear epitopes derived from the spike and nucleocapsid protein. Anti-M is also present in the convalescent phase of COVID-19 patients, however at lower levels, with the N-terminus of the M protein as a preferred target.